03/24/2020
is effective in treating new ( ), China's prove. Hydroxychloroquine can effectively relieve symptoms, reverse the rate of exacerbation, and shorten the course of disease
20 coronavirus covid-19 patients had significantly improved clinical symptoms after 1-2 days of treatment with hydroxychloroquine, and no disease progression occurred. The clinical trial was conducted by the University People's Hospital.
As of March 15, a total of 180 patients were enrolled and 21 hospitals participated the study of hydroxychloroquine in the of COVID-19 in .
On February 4th, the Wuhan University People's Hospital research group registered the "Effectiveness of Hydrochlorochloroquine on the New Coronavirus (COVID-19)" after it was approved by the Ethics Committee of Wuhan University People's Hospital and registered it on the clinical trial platform (registration number: ChiCTR2000029559). As of February 17, the hospital's "hydroxychloroquine + basic treatment group" enrolled 20 patients with COVID-19, and found that the clinical symptoms of patients improved significantly after 1-2 days of treatment with hydroxychloroquine. A review of chest CT after 5 days of use showed a significant improvement in absorption in 19 patients; only 1 patient (previously had renal insufficiency) had progress in chest CT, but the patient's clinical symptoms improved significantly on the second day of hydroxychloroquine use. In addition, none of the normal patients enrolled in the group progressed to severe disease, and one of them was discharged on February 13.
The results of this clinical trial have initially confirmed the short-term efficacy of hydroxychloroquine in the treatment of COVID-19, which can effectively relieve symptoms, reverse the rate of exacerbation, and shorten the course of disease. Two of the 20 patients had adverse reactions of mild rash and mild headache, and all of them were relieved in time after adjusting the medication.
Hydroxychloroquine is a mature immunosuppressive agent for clinical application. It also has , , , optical filter, anticoagulant effects, and has fewer adverse reactions. It is also a basic drug for patients with systemic lupus erythematosus. The Wuhan University People's Hospital research team conducted a clinical analysis of 178 COVID-19 patients admitted to the hospital from December 2019 and found that none of them were patients with systemic lupus erythematosus. Later, in consultation with 80 patients with systemic lupus erythematosus treated in the dermatology department of the hospital, they were found not to be infected with COVID-19.
The Department of Respiratory and Critical Care Medicine, Dermatology, and Rheumatology of the People's Hospital of Wuhan University jointly discussed that the patients with systemic lupus erythematosus received by the hospital were not infected with COVID-19. Is it related to their long-term use of hydroxychloroquine? In view of the urgency of the epidemic, and no effective anti-coronavirus drugs, and hydroxychloroquine has both antiviral and immunomodulatory effects, the research team proposed to conduct clinical trials of hydroxychloroquine in patients with COVID-19.
In the absence of effective drugs, Shanghai is also actively promoting a number of drugs that have been marketed, or at least have a certain clinical research basis, including hydroxychloroquine, etc., to carry out research and development of new indications for COVID-19.
Among them, chloroquine has shown good anti-new coronavirus activity in in vitro studies and has been used as a clinical trial drug by the Ministry of Science and Technology and the Health and Health Commission. A few days ago, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Pharmaceutical Group jointly launched a clinical trial of hydroxychloroquine in the treatment of COVID-19 at the Shanghai Public Health Clinical Center.
In terms of research on new drugs for the treatment of COVID-19, Shanghai is organizing advantageous forces to accelerate the speed of new drug discovery and research. The Shanghai University of Science and Technology research team determined the high-resolution crystal structure of the new coronavirus 3CL hydrolase (Mpro), which can be provided to scientific and technological personnel for drug development to carry out new drug research.
As of March 15, a total of 180 patients were enrolled and 21 hospitals participated the study of hydroxychloroquine in the treatment of COVID-19 in China
sources:
https://www.xianjichina.com/news/details_186224.html
https://new.qq.com/omn/20200316/20200316A0F3EX00
